ArticleJournal of chemical information and modeling2025
Computational Pipeline for Accelerating the Design of Glycomimetics.
Article in Journal of chemical information and modeling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Selectivity: Improving Golgi α-Mannosidase II (GMII) Inhibitors Through In Silico Studies.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
To accelerate the rational design of glycomimetic inhibitors, based on derivatization of a carbohydrate ligand, we introduce a computational pipeline that automates the creation and modeling of analogs and computes their interaction energies. Putative glycomimetics are assembled by grafting small drug-like moieties onto the native carbohydrate scaffold in the presence of the receptor protein, with the moieties chosen from a virtual library of more than 1500 molecular fragments, selected for their synthetic accessibility. The method is illustrated for the case of glycomimetics but is generalizable to any bound ligand. A genetic algorithm (GA) was developed to identify the most likely orientation of the appended moieties in the receptor binding site. For validation, curated experimental data sets were assembled from the literature, consisting of 119 glycomimetics, with reported solution binding free energies, including 46 with corresponding high-resolution crystal structures of the glycomimetic complexes. These data sets were subdivided for protocol testing and "real-world" performance validation. The GA search resulted in an average root-mean-squared deviation (RMSD) of 1.5 Å for the added moieties, compared to their crystallographic data. The GA-generated structures were then subjected to molecular dynamics (MD) simulation, and the performance was evaluated for three post-MD approaches to computing interaction energies: the scoring function from AutoDock Vina-Carb, as well as the generalized Born and Poisson-Boltzmann surface area (GBSA/PBSA) implementations within the AMBER molecular mechanical (MM) force field. For the Test data set of structures with reported energies, the highest coefficient of determination (R
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.